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study question: How well can a single baseline ultrasound assessment of fibroid burden (presence or absence of fibroids and size of
largest, if present) predict future probability of having a major uterine procedure?
summaryanswer: During an 8-year follow-up period, the risk of having amajor uterine procedurewas 2% for thosewithout fibroids and
increased with fibroid size for those with fibroids, reaching 47% for those with fibroids ≥4 cm in diameter at baseline.
what is known already: Uterine fibroids are a leading indication for hysterectomy.However, when fibroids are found, there are few
available data to help clinicians advise patients about disease progression.
study design, size, duration:Womenwhowere 35–49 years old were randomly selected from themembership of a large urban
health plan; 80%of those determined to be eligiblewere enrolled and screenedwith ultrasound for fibroids≥0.5 cm in diameter. African-Ameri-
can and white premenopausal participants who responded to at least one follow-up interview (N ¼ 964, 85% of those eligible) constituted the
study cohort. During follow-up (5822 person-years), participants self-reported any major uterine procedure (67% hysterectomies). Life-table
analyses and Cox regression (with censoring for menopause) were used to estimate the risk of having a uterine procedure for women with no
fibroids, small (,2 cm in diameter), medium (2–3.9 cm), and large fibroids (≥4 cm). Differences between African-American and white
women, importance of a clinical diagnosis of fibroids prior to study enrollment, and the impact of submucosal fibroids on risk were investigated.
participants/materials, setting, methods: There was a greater loss to follow-up for African-Americans than whites (19
versus 11%). For thosewith follow-up data, 64% had fibroids at baseline, 33% of whomhad had a prior diagnosis. Of thosewith fibroids, 27% had
small fibroids (,2 cm in diameter), 46% had medium (largest fibroid 2–3.9 cm in diameter), and 27% had large fibroids (largest ≥4 cm in diam-
eter). Twenty-one percent had at least one submucosal fibroid.
main results and the role of chance: Major uterine procedures were reported by 115 women during follow-up. The esti-
mated risk of having a procedure in any given year of follow-up for those with fibroids compared with those without fibroids increased markedly
with fibroid-size category (from4-fold, confidence interval (CI) (1.4–11.1) for the small fibroids to 10-fold,CI (4.4–24.8) for themediumfibroids,
to 27-fold,CI (11.5–65.2) for the large fibroids). This influenceof fibroid size on risk did not differ betweenAfrican-Americans andwhites (P-value
for interaction ¼ 0.88). Once fibroid size at enrollment was accounted for, having a prior diagnosis at the time of ultrasound screening was not
predictive of having a procedure. Exclusion of womenwith a submucosal fibroid had little influence on the results. The 8-year risk of a procedure
basedon lifetable analyseswas2% forwomenwith no fibroids, 8, 23, and47%, respectively, forwomenwhohad small,mediumor large fibroids at
enrollment. Given the strong association of fibroid size with subsequent risk of a procedure, these findings are unlikely to be due to chance.
Published byOxfordUniversity Pressonbehalf of the European Society ofHumanReproduction and Embryology2015.Thiswork iswrittenby (a)USGovernment employee(s) and is in the public
domain in the US.
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limitations, reasons for caution: Despite a large sample size, the number of women having procedures during follow-up was
relatively small. Thus, covariates such as BMI, which were not important in our analyses, may have associations that were too small to detect with
our sample size. Another limitation is that themedical procedureswere self-reported. However, we attempted to retrievemedical recordswhen
participants agreed, and 77%of the total procedures reportedwere verified.Our findings are likely to be generalizable to otherAfrican-American
and white premenopausal women in their late 30s and 40s, but other ethnic groups have not been studied.
wider implications of the findings: Though further studies are needed to confirm and extend the results, our findings provide
an initial estimate of disease progression that will be helpful to clinicians and their patients.
study funding/competing interest(s): Funding came from the Intramural Research Program of the National Institute of En-
vironmental Health Sciences and the Office of Research on Minority Health, National Institutes of Health, Health and Human Services (IRB
#OH95-E-N048). The authors have no conflicts of interest.
trial registration number: Not applicable.
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Introduction
Uterine leiomyomata (fibroids) are hormonally dependent benign
tumors that develop during reproductive years in the majority of
women (Stewart, 2001; Baird et al., 2003).Manywomen are asymptom-
atic, but others experience heavy vaginal bleeding, pelvic pain and/or re-
productive problems (Stewart, 2001; Divakar, 2008). There is marked
racial/ethnic disparity in the development of fibroids, with disease
onset estimated to be 10–15 years earlier for African-Americans than
for whites (Laughlin et al., 2010b). Fibroids are a leading indication for
hysterectomy (Vessey et al., 1992; Farquhar and Steiner, 2002; Marret
et al., 2012). African-Americans have a particularly high rate of hysterec-
tomy for fibroids, 20%by age ofmenopause comparedwith 7% inwhites
(Myers et al., 2001). The cost of this condition in the USA is estimated at
$6–34 billion annually (Cardozo et al., 2012).
Clinical diagnosis of fibroids can occur at all stages of disease
development from small, incidentally identified tumors to large
symptomatic tumors (Divakar, 2008; Laughlin and Stewart, 2011).
Without an approved pharmacologic treatment that limits fibroid
growth and delays symptoms, there has been no impetus for early
diagnosis. Initial treatment is usually focused on watchful waiting or
symptom reduction with analgesics or hormonal contraceptives. In
most cases the fibroids themselves are treated only if symptoms are
severe. The primary options for women with severe symptoms are
major uterine procedures including uterine artery embolization, MRI-
guided focused ultrasound, and surgery (Segars et al., 2014). Hysterec-
tomy has long been the mainstay treatment in the USA (Laughlin and
Stewart, 2011).
Little is known about disease progression (Jacoby et al., 2014),
though this would be helpful for counseling women. Some women
have a major uterine procedure soon after initial clinical diagnosis
(Hartmann et al., 2006), while others never have such treatment. Of
the five longitudinal studies of fibroid growth (Ichimura et al., 1998;
Tsuda et al., 1998; DeWaay et al., 2002; Peddada et al., 2008; Mavrelos
et al., 2010), all were short-term and all reported that the individual
tumor growth rates were highly variable. The largest study (n ¼ 262
fibroids followed with MRI for up to a year) found a median growth
of 9% per 6 months, but rates varied from 89% shrinkage to 138%
growth per 6 months (Peddada et al., 2008). Data from the same
sample of tumors showed that rapid growth often came in spurts and
was rarely sustained over time (Baird et al., 2011). Thus, long-term
growth might be quite different from the short-term growth that has
been studied. Almost nothing is known about symptom development
in relation to fibroid growth, though data indicate that women with
large fibroids are more likely to have symptoms than those with small
fibroids (Stewart, 2001; DeWaay et al., 2002; Wegienka et al., 2003;
Dragomir et al., 2010).
The National Institute of Environmental Health Sciences Uterine
Fibroid Study used ultrasound to screen a large, randomly selected
sample of premenopausal African-American and white women for
fibroids. Study participants were then followed for up to 8 years to
assess the occurrence of major uterine procedures. We report the
association between the single baseline ultrasound assessment for
presence of fibroids and tumor size (if present) and the subsequent
occurrence of a major uterine procedure.
Materials andMethods
Study design
The Uterine Fibroid Study (UFS) is a prospective cohort study.Women, age
35–49 years, were randomly selected from the membership list of a large
urban health plan and contacted about the study. Approximately 80% of
those found to be eligible were enrolled, and response was similar for
African-Americans and whites (Baird et al., 2003). At enrollment, which oc-
curred in 1996–1999, premenopausal participants attended a clinic visit to
give blood, have measurements taken (weight, blood pressure, waist and
hip circumference), and have ultrasound screening for fibroids (unless a
recent sonogram report was available from a recent clinical examination).
Study participants were followed for up to 8 years with interviews to
assess subsequentmedical procedures (interview1 in 2001–2002, interview
2 in 2004).
Participants
The initial study population consisted of 1430 women of whom 1323 were
African-American or white women. Fourteen percent of these (n ¼ 182)
were post-menopausal at enrollment (mostly surgically menopausal) and
were not followed prospectively. Eighty-five percent of the 1141 premeno-
pausal African-American and white women eligible for follow-up completed
either the first follow-up, the second follow-up, or both (N ¼ 964, Fig. 1).
Those lost to follow-upwere not substantially different from the participants
of the same ethnic group not lost to follow-up based on comparisons of de-
scriptive variables such as age, education, body mass index, smoking habits,
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gravidity or parity. However, a larger percentage of African-Americans were
lost to follow-up than whites (18.6 versus 10.8%). At enrollment, fibroid
status could not be determined for 8% of African-Americans and 6% of
whites (they did not complete the baseline ultrasound and no other data
were available). These women were also excluded from this analysis (final
analysis sample ¼ 895).
Fibroid status assessment
Pelvic ultrasound examinations were used to assess participant’s fibroid
status regardless of whether or not the participant had had a prior clinical
diagnosis of fibroids. For those who had recently had a pelvic ultrasound
examination (16%), the radiology records from that examination were
used to assess fibroid status. If the prior examination showed no fibroids
and was done within 2 years, it was used; a sonogram showing fibroids was
used if it had been done within 5 years. The study ultrasound for the remain-
der includedboth a transabdominal and transvaginal ultrasoundexamination.
The abdominal portion was used to evaluate any fibroid that arose from the
upper uterus that would not be readily seen with the transvaginal approach
alone. Ultrasound examinations were conducted by experienced sonogra-
phers that were certified by the American Registry of Diagnostic Medical
Sonographers and trained on the study protocol. They were under the
direct supervision of a radiologist with fellowship training in ultrasound
(author M.C.H.). The examinations were performed on ultrasound units
ATL HDI 9, Acuson 128 XP, and Diasonics DRF 400 using transabdominal
(3.5–5.0 mHz) and transvaginal (5.0–7.0 mHz) ultrasound probes. The
uterus andfibroidsof≥0.5 cmwere identified. Sizeof theuterus (volumecal-
culated from three perpendicular diameters using the ellipsoid formula) and
size of the largest fibroid (largest diameter) weremeasured. Any submucosal
fibroids were noted. Submucosal was defined as adjacent to the endomet-
rium with no visible normal myometrium between endometrium and
fibroid. Any questionable sonograms were reviewed by a single radiologist
(M.C.H.). We relied on self-report of fibroid size for a small subset of the
sample who reported a previous fibroid diagnosis, but did not complete
the study ultrasound (n ¼ 28). Exclusion of these women did not change
our findings. We categorized size of largest fibroid (no fibroids, largest
fibroid ,2 cm, 2–,4 cm, ≥4 cm).
Assessment of major uterine procedures
during follow-up
Follow-up telephone interviews were conducted first in 2001–2002 and
again in 2004.We gathered self-reported information on major uterine pro-
cedures (excluding pregnancy procedures). Women were asked specifically
about hysterectomy, myomectomy, hysteroscopic resection, uterine artery
embolization, endometrial ablation and ‘other’. The only ‘other’ procedure
reportedwas thermal balloon ablation of the endometrium.Wewere able to
collect medical records and confirm 88 of the 115 procedures identified. Six
participants refused at the follow-up interview to release their medical
records, 11 agreed but never returned the signed medical release form,
and for 10 the medical provider failed to return the relevant information.
Other enrollment and follow-up data
Baseline interviews asked about demographic information (age, race/ethni-
city and education), height, weight history, a full reproductive history, and
lifestyle information including smoking and alcohol drinking. Baseline
weight was measured at the clinic visit. At each follow-up, interviews asked
about information on menstrual characteristics, time of last menstrual
period, menopausal symptoms, weight, any pregnancies since last interview,
and updated lifestyle information. All interviews were conducted by inter-
viewers who were intensively trained on basic interview procedures and
the study interviews in particular. Interviewers completed mock interviews
Figure 1 Flow chart showing the sample of National Institute of Environmental Health Sciences Uterine Fibroid Study participants available for this
analysis.
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that were monitored and approved before they collected data from partici-
pants, and occasional ongoing interviews were monitored. The staff for each
of the three interviews numbered 10, 15, and 12 interviewers for baseline,
follow-up 1, and follow-up 2, respectively, with several interviewers from
baseline continuing with follow-up interviews.
Statistical analysis
Analyses were initially conducted for African-Americans and whites separ-
ately.We used discrete proportional hazards models to evaluate the associ-
ation between fibroid size at enrollment and risk of future major uterine
procedures. Time since enrollment was used as the longitudinal variable,
and data were censored at menopause or end of follow-up. The strength
of associationwasestimatedwith ahazard ratio,whichestimates riskof a sub-
sequent procedure for women in each baseline fibroid-size category relative
towomenwithnofibroids at baseline. Thepotential confounderswere age at
baseline (enrollment), bodymass index (BMI) and recent births, whichmight
lead to fibroid regression (Laughlin et al., 2010a,b, 2011). BMI andbirthswere
entered as time-dependent variables using both baseline and follow-up data.
BMI was categorized as shown in Table I. For births that occurred during
follow-up, time since birth was coded as continuous in years starting with
‘0’ for the year of the birth. Years prior to any follow-up birth were coded
as ‘9’. Thus, the time-dependent 8-year coding for a participant who had
one birth during the third year of follow-up would be 9,9,0,1,2,3,4,5.
Those not having a birth during follow-up were coded as ‘9’ throughout
their follow-up years. Adjusting for age changed at least one of the hazard
ratios by at least 10% and was the only potential confounder maintained in
the model. We tested for ethnic differences in the association between
fibroid size and the probability of a procedure by combining data for
African-Americans and whites and including interaction terms for ethnicity
by category of fibroid size. Because the associations were similar for
African-Americans and whites (no interaction) we report the hazard ratios
for the combined data set, controlling for ethnicity.
Absolute cumulative risks of a procedure across follow-up time for separ-
ate fibroid size categories were calculated using life-table analyses. Women
were followed in the life table until the first reported date of either a
uterine procedure, menopause (date of last menstrual period plus 1 year),
or end of follow-up (date of last follow-up interview).
Two secondary analyses were conducted. First we investigated whether
women with a diagnosis of fibroids prior to study enrollment were more
likely to have a procedure even after baseline fibroid size was taken into
account, i.e. the impact of including a variable for prior diagnosis in the
hazardmodel. Secondly,we investigated the influenceof submucosal fibroids
by re-running the primary hazard model after excluding women with at least
one submucosal fibroid.
Ethical approval
The research was approved by the NIEHS and GeorgeWashington Univer-
sityHuman Subjects ReviewBoards, and participants gave informed consent.
Results
The age distributions of white (N ¼ 380) and African-American
(N ¼ 515) study participants were very similar (Table I). Most had
more than a high school education, but white women tended to have
more education and lower BMI than African-Americans. Only about
40% of whites had given birth, but most African-Americans were
parous. About half of white women had fibroids, and about 20% of
those had large fibroids (≥4 cm diameter). Nearly three-quarters of
African-Americans had fibroids, and nearly a third of those had large
tumors. The majority of whites with fibroids (68%) were new cases
(fibroids were found at the baseline ultrasound, and there had been no
previous diagnosis), while the majority of African-Americans with
fibroids had been previously diagnosed (61%) (Table I).
Womenwere followed for up to8years (5822person-years of follow-
up, whites ¼ 2502, African-Americans ¼ 3320). Of the 895 women,
800 participated in both follow-ups, while 57 participated in only the
first follow-up and 38 participated in only the second follow-up. Twenty-
four percent of white women and 20% of African-American women
went through natural menopause during follow-up. Follow-up time
after menopause was not considered in analyses because fibroids
often begin to shrink after menopause. A total of 115 women reported
major uterine procedures during the follow-up (29 white and 86
African-Americanwomen). Themajorityof the procedureswerehyster-
ectomies andmyomectomies (Table II). The symptoms that led tohaving
a major uterine procedure were mostly bleeding and pelvic pain
(Table III).
Only 6 of the 323 women without fibroids at enrollment went on
to have a major uterine procedure during their follow-up (2 African-
American women and 4 white women). All were hysterectomies, five
for endometriosis or prolapse, and one for both adenomyosis and
fibroids.
The hazard ratios for having a procedure during follow-up increased
dramatically with the fibroid-size category in both African-Americans
and whites. When we combined African-Americans and whites to test
for ethnic differences in the association between fibroid size at enroll-
ment and risk of a uterine procedure during follow-up, we found no
evidence for ethnic differences (P ¼ 0.88). In the combined data the
hazard ratio for a uterine procedure, adjusted for age and ethnicity
(aHR), rose dramatically with size of the largest fibroid (aHR ¼ 4.0,
95% CI ¼ 1.4–11.1 for ,2 cm, aHR ¼ 10.4, 95% CI ¼ 4.4–24.8 for
2–,4 cm, and aHR¼ 27.4, 95%CI ¼ 11.5–65.2 for≥4 cm) (Table IV).
In secondary analyses we consideredwhetherwomenwho had a clin-
ical diagnosis of fibroids prior to study enrollment (52% of those with
fibroids), were more likely to have a procedure during follow-up than
those whose fibroids were first identified at the study ultrasound.
When ‘prior diagnosis’ was included in the hazard model along with
the categories for fibroid size, it was not significantly related to having a
major uterine procedure during follow-up (aHR ¼ 1.4, 95% CI ¼ 0.9–
2.2), and the aHRs for each fibroid-size category were not substantially
different from the estimates from the model without adjustment for
prior diagnosis.Whenwe investigated the impact of submucosal fibroids
by excluding the 118 women who had at least one such fibroid, the
fibroid-size-specific hazard ratios did not change substantially (aHR ¼
2.9 for small, 10.4 for medium, and 31.6 for large fibroids) (Supplemen-
taryTable SI).Norwas having a submucosal fibroid a significant predictor
of subsequent procedures when it was included as a variable in a hazard
model that included fibroid size (P ¼ 0.59).
Our life-table analysis to calculate the fibroid-size-specific cumulative
risk of a procedure over the up to 8-year follow-up is shown in Fig. 2. For
thosewithout fibroids at baseline, the cumulativeprobabilityof a proced-
ure at 8 yearswas 2%; it was 8, 23 and 47% for thosewith small, medium
and large fibroids, respectively. For the latter group, the cumulative riskof
a procedure increased rapidly from the start of follow-up, reaching over
10%during the first year, 20%by theendof 2 years, and30%by theendof
4 years. The cumulative risk for those with medium fibroids exceeded
10% only after 4 years of follow-up. Those with small fibroids still had
only about a 5% cumulative risk after 4 years.
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Table I Descriptive characteristics at enrollment, sample fromNational Institute of Environmental Health Sciences
Uterine Fibroid Study.
Whites
380
African-Americans
515
N (%) N (%)
Year of enrollment
1996 72 (19) 96 (19)
1997 160 (42) 224 (44)
1998 148 (39) 193 (37)
1999 0 (0) 2 (,1)
Age at baseline (years)
35–37 77 (20) 109 (21)
38–40 76 (20) 116 (23)
41–43 78 (21) 113 (22)
44–46 82 (21) 109 (21)
47–50 67 (18) 68 (13)
Education
,High school 0 (0) 9 (2)
High school 11 (3) 91 (18)
Some college/no degree 30 (8) 240 (46)
College degree 64 (17) 68 (13)
College plus additional training 62 (16) 45 (9)
Post graduate degree 212 (56) 60 (12)
Missing 1 – 2 –
BMI (kg/m2)
,25 222 (58) 133 (26)
25–29 91 (24) 154 (30)
30,35 33 (9) 104 (20)
≥35 34 (9) 124 (24)
Smoking
Never 223 (59) 250 (49)
Past 131 (34) 115 (22)
Current
,10 cigarettes per day 9 (2) 73 (14)
10–20 cigarettes per day 10 (3) 37 (7)
≥20 cigarettes per day 7 (2) 40 (8)
Gravidity
0 152 (40) 46 (9)
≥1 228 (60) 469 (91)
Parity
0 223 (59) 110 (21)
1 50 (13) 117 (23)
≥2 107 (28) 288 (56)
Fibroids diagnosed prior to enrollment
Yes 61 (16) 234 (45)
No 319 (84) 281 (55)
Fibroids at baselinea
Yes 189 (50) 383 (74)
No 191 (50) 132 (26)
Continued
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Discussion
We followed premenopausal women ages 35–49 years who had
been randomly selected at baseline from a large health plan. The
8-year probability of having a major uterine procedure was highly
dependent on ultrasound assessed fibroid status at baseline (presence
or absence of fibroids and size of largest, if present). Women with no
evidence of fibroids at baseline had only a 2% cumulative probability of
a uterine procedure, but it rose to 47% for those who had baseline
fibroids ≥ 4 cm in diameter.
Consistent with other studies (Laughlin et al., 2010b), at enrollment
African-American study participants were more likely than whites to
have fibroids, and their fibroids were larger (Baird et al., 2003).
However, when we conducted the follow-up, the probability of a
major uterine procedure during follow-up was similar for African-
Americans and whites once baseline fibroid size was taken into
account. A previous study that reported higher rates of hysterectomy
for blacks with fibroids compared with whites with fibroids (Bower
et al., 2009) did not take fibroid size into account.
Our study has several strengths. No previous study has assessed
fibroid status with ultrasound data on fibroid size in a randomly selected
sample of women and then followed them to determine the risk of
a major uterine procedure. Initial response rates were high, thus
limiting selection bias in our findings. Our sample included both
African-American and white women in sufficient numbers to evaluate
each group separately. The standardized ultrasound examination
reduced misclassification of presence and absence of fibroids, and pro-
vided a standardized measure of fibroid size. Our detailed questionnaire
data allowed us to evaluate confounding and censor women when they
became naturally menopausal during the follow-up.
Our study also has limitations. We followed women to assess their
major uterine procedures, butwewere not able to do periodic systematic
........................................ .........................................
.............................................................................................................................................................................................
Table I Continued
Whites
380
African-Americans
515
N (%) N (%)
Fibroid size (diameter of largest fibroid)
No fibroids 191 (50) 132 (26)
,2 cm 66 (17) 89 (17)
2–3.99 cm 80 (21) 184 (36)
≥4 cm 43 (11) 110 (21)
Fibroid type
No fibroids 191 (51) 132 (27)
Submucosal 37 (10) 81 (17)
No submucosal 144 (39) 274 (56)
Missing fibroid type 8 – 28 –
aIncludes newly detected and previously diagnosed.
..................... ...........................
........................................................................................
Table II Major uterine procedures during 8 years of
follow-up, National Institute of Environmental Health
Sciences Uterine Fibroid Study.
Whites African-Americans
Total N5 29 (%) N 5 86 (%)
Hysterectomy 13 (45) 64 (74)
Myomectomy 9 (31) 4 (5)
Hysteroscopic resection 5 (17) 7 (8)
Uterine artery embolization 0 (0) 9 (11)
Endometrial ablation 2 (7) 1 (1)
Thermal balloon 0 (0) 1 (1)
........................................................................................
Table III Reported symptomsthat led tohavingamajor
uterine procedure during 8 years of follow-up, National
Institute of Environmental Health Sciences Uterine
Fibroid Study.
Symptom Number of times
reporteda
Bleeding 72
Pelvic pain 50
Back Pain 8
Urinary incontinence or urinary frequency 6
Infertility 4
Constipation/diarrhea 2
Leg pain 1
Don’t know 1
Other, non-fibroid relatedb 7
aWomen can reportmultiple symptoms. Six womenweremissing data on symptoms,
and four reported that they did not have symptoms.
bIncludes items such as endometriosis, prolapse and cervical dysplasia.
6 Baird et al.
 at G
eorge W
ashington U
niversity on O
ctober 15, 2015
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
ultrasound examinations during follow-up. Unlike a direct measure of
fibroid growth, our measure of disease progression (time to major
uterineprocedure)will vary bothwithwomen’s perceptions of symptoms
and with clinical practice. Also, though our baseline sample size was rela-
tively large, the number of women who underwent a procedure was
limited, so small effects would not have been detected. For example,
covariates such as BMImay have effects on the risk of a uterine procedure
that were too small for our study to detect. We had too few Hispanic or
Asian women to evaluate risk of a procedure for these groups.
Anaspectof our design thatmight have led tobias is thatour studypar-
ticipants were told their fibroid status after the baseline ultrasound.
Nearly half (48%) had not been previously diagnosed. It seems possible
that this knowledge could have affected their perceptions of symptoms
and future decisions to havemajor uterine procedures. However, a pre-
vious investigation found no evidence that symptom reporting was influ-
enced by knowledge of fibroids (Wegienka et al., 2004), and treatment is
generally reserved for those with symptoms (Stein and Ascher-Walsh,
2009). Furthermore, when we evaluated the influence of having had a
clinical diagnosis of fibroids before baseline, it was not important once
we accounted for tumor size at baseline. Another limitation is that the
uterine procedures were self-reported, but most were verified with
medical records.
Perhaps the most important limitation is that we used a single, simple
measure to assess fibroid status at baseline (fibroid presence or absence
and size of largest, if present). Othermeasures of fibroid burden need to
be investigated such as categories of submucosal, intramural, or subser-
osal as recommendedby the International FederationofGynecology and
Obstetrics (FIGO) (Munro et al., 2011). We did not have sufficiently
detailed fibroid data to use the full FIGO categorization, but we did con-
sider the influence of submucosal fibroids. First, we excluded women
with any submucosal fibroids. Then we reanalyzed the full data set
with the dichotomous variable ‘any submucosal fibroid’ added to
control for this factor. Neither including the dichotomous variable nor
excluding women with submucosal fibroids changed the results in any
substantial way. However, this sensitivity analysis relies upon our ultra-
sound measure of fibroid location, which is less accurate than the
more invasive procedures of infusion sonography or hysteroscopy.
To furtherexplore alternativewaysof defining baseline fibroid burden,
we have also conducted supplemental analyses using a tumor burden
variable that includes baseline uterine size. This has the advantage of in-
tegrating the impact of multiple fibroids (Supplementary Table SII). This
definition of fibroid burden was again highly predictive. The estimated
risk of a procedure for women with the highest uterine-size category
(≥250 cm3) was 45-fold higher than for the women with no fibroids at
baseline. In addition, the association between this measure of fibroid
burden with risk of a future major uterine procedure was similar for
African-Americans and whites (P-value for interaction ¼ 0.92).
The similar predictive power of simple measures of fibroid burden in
35–49 year-old African-American and white women may be surprising,
given the higher fibroid prevalence and symptom severity in
African-Americans. However, it is consistent with the idea that the
African-American/white disparity in fibroid-related health issues is pri-
marily attributable to the approximately 10-year earlieronset of this con-
dition in African-American women, not to a difference in how fibroids
impact symptomatology once the tumors are present.
Large fibroids are more likely to cause health problems than small
fibroids (Stewart, 2001; Wegienka et al., 2003; Dragomir et al., 2010),
but information on the natural history of fibroid development is limited
(Ichimura et al., 1998; Tsuda et al., 1998; DeWaay et al., 2002;
Peddada et al., 2008; Mavrelos et al., 2010). The data on short-term
fibroid growth indicate that individual fibroids grow at different rates,
and sporadic growth spurts are common (Peddada et al., 2008; Baird
et al., 2011). Thus, it would not have been surprising to find that data
from a single ultrasound would have little predictive benefit. Instead,
the single ultrasound assessment of fibroid size was highly predictive of
future uterine procedures. It is likely that several of the women who
had no fibroids at enrollment developed them during follow-up, but
they remained at low cumulative risk of a procedure. This suggests that
it is rare for fibroids to cause major problems during the first few years
of their development. Likewise, women with small fibroids at baseline
were at low cumulative risk. This may indicate that, despite variation in
growth rates, it usually takes many years for small fibroids to grow to a
size that lead to major uterine procedures. A careful, long-term study
of fibroid growth with periodic assessment of fibroid size is needed.
Medical management of fibroids may be at the cusp of transition.
There is a current effort to find pharmacological treatments that shrink
Figure2 Cumulative probability of having a major uterine procedure
for womenwith increasing fibroid size (categories based on diameter of
largest fibroid), National Institute of Environmental Health Sciences
Uterine Fibroid Study.
........................................................................................
Table IV Crude and adjusted hazard ratios (HR) for
having amajor uterine procedureassociatedwith fibroid
size at enrollment (diameter of largest fibroid), National
Institute of Environmental Health Sciences Uterine
Fibroid Study 8-year follow-up (N 5 895).
Fibroid size N HR 95% CIb aHRa 95% CIb
No fibroids 323 1.0 – 1.0 –
,2 cm 155 3.9 1.4–10.6 4.0 1.4–11.1
2–3.99 cm 264 10.4 4.4–24.5 10.4 4.4–24.8
≥4 cm 153 26.7 11.6–62.4 27.4 11.5–65.2
aModels adjusted for age and ethnicity.
bCI, confidence interval.
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fibroids and reduce symptoms (Sabry and Al-Hendy, 2012). Ulipristal
acetate, a selective progesterone receptor modulator, is one such treat-
ment that has been approved for pre-surgery use in Europe and Canada
(Croxtall, 2012; Donnez et al., 2012; Talaulikar and Manyonda, 2012).
Recent studies of up to four 3-month treatment intervals have demon-
strated that ulipristal acetate may effectively manage fibroid symptoms
over time; many study participants opted to forego surgery (Galliano,
2015). Our estimates of time without a treatment procedure in
women in different fibroid-size categories could assist in developing effi-
cient study designs for further investigations of non-invasive treatment
strategies.
In conclusion, we found that the 8-year cumulative probability of
having amajor uterine procedure for 35–49 year-oldwomen varied sub-
stantially by baseline fibroid burden, as measured in a single ultrasound
examination. There was a similar increase in risk for African-American
and white women, and the data are likely to be generalizable to other
women of these ethnic groups in their late 30s and 40s. Though
further studies are needed to confirm and extend our findings, our
data on disease progression provide initial estimates that will be very
helpful for counseling women.
Supplementary data
Supplementarydata areavailable athttp://humrep.oxfordjournals.org/.
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